It is called Te Papa Hauora, the Christchurch Health Precinct and what began as a rebuilding project after the 2010–2011 Canterbury earthquakes has evolved into something closer to a deliberate industrial strategy. Cumulative investment across its public hospital rebuilds, university and polytechnic campuses, and commercial healthtech space now runs well past the billion dollar mark and the momentum is starting to attract attention well beyond New Zealand's shores.

Switzerland's medical technology industry is having a strange kind of year. By almost every headline measure, it is thriving: output is expanding at twice the rate of the broader Swiss economy, exports are climbing, and research spending remains among the highest of any industrial sector in the country. Yet beneath those numbers, the people who run the country's medtech companies are sounding an alarm that has been building for several years and has now become impossible to i

The NHS IT market is entering one of its most consequential growth phases in years. New analysis from Future Health Intelligence (FHI) forecasts that spending on NHS technology will climb from £6.1bn today to £8.3bn by 2030, adding more than £2bn in new market value over the next four years and cementing digital health as one of the fastest-growing corners of the UK public sector IT landscape. For an industry that has weathered its share of false starts and stop-go funding cy

Transformation Capital, the largest dedicated digital health venture and growth equity firm, has announced the final close of its fourth fund, Transformation Capital Fund IV, at an $850 million hard cap. The raise came in oversubscribed, with the firm completing the close this summer after exceeding its original target. It's a milestone that says as much about the state of digital health investing in 2026 as it does about Transformation Capital itself, and it's worth unpackin

There was no keynote, no press release, no carefully art-directed product shot. Apple's latest acquisition surfaced the way most of its acquisitions do: through a regulatory filing nobody was supposed to notice. Buried in the European Union's database of mergers likely to be significant in the region, a single entry revealed that Apple had acquired Sonera, a Berkeley born startup that builds non-invasive sensors capable of reading neural signals straight from the brain and bo

On 14th September 2026, Stockholm-based Tandem Health announced a $100 million (€86.5 million) Series B led by the Scaleup Europe Fund, the €5 billion vehicle managed by EQT and seeded by the European Commission, Novo Holdings, CriteriaCaixa and Santander. Existing backers Kinnevik, Northzone, Amino Collective and Visionaries all followed on. The round takes Tandem's total funding to roughly $160 million, barely fifteen months after its $50 million Series A and makes it the b

We tend to think of health security in terms of things we can see under a microscope or feel in a fever. Pandemics, antimicrobial resistance, contaminated water, the next novel virus. These are the threats that governments plan for, that the World Health Organization tracks and that most of us instinctively recognise as matters of life and death. There is a newer threat on that list, and it does not come from a pathogen. It comes from a laptop, often thousands of miles away,

OpenEvidence has established itself as the preeminent artificial intelligence platform in United States clinical practice, commonly referred to across the digital health ecosystem as the "ChatGPT for Doctors". Conceived by serial technologist Daniel Nadler and machine learning researcher Zachary Ziegler, the platform was developed to address an acute structural crisis in modern medicine: the velocity of peer-reviewed biomedical literature, which currently doubles every 73 day

The European digital health and healthcare technology sector is undergoing an institutional realignment. Valued at approximately $96.68 billion in 2025 and projected to expand to $222.22 billion by 2030 at a compound annual growth rate (CAGR) of 18.11%, the market has moved beyond the speculative retail funding cycles that characterised the zero interest rate policy (ZIRP) era. Alongside this software-driven expansion, the broader European medical technology industry maintai

Activity across European HealthTech this week centred on remote patient monitoring, clinical AI infrastructure, and EU-backed commercial rollouts. Activity across European Health AI this week centred around digital twins, Neuro AI and guidelines for the use of AI across the NHS. Activity across European MedTech this week centred on implants, preventative imaging, regulation and rehabilitation.

So is Apple coming for WHOOP and Oura? The short answer is yes, but not in the way most commentators expect. Apple is unlikely to try to out-WHOOP WHOOP. It is far more likely to reframe the category so that recovery scores become a commodity feature of the platform and the real battleground shifts to something only Apple can do at scale: turning a billion-plus devices into a clinically credible, longitudinal health record with a services layer on top.

We expect 2027 to be remembered as the year that HealthTech investors and founders stopped treating hardware as the difficult, capital hungry cousin of software and started treating it as the foundation of a defensible business. The moat, it turns out, was never the code. It was the thing the code runs on.

The consumer digital health sector is undergoing a structural transition from episodic, reactive vital sign tracking toward continuous, multimodal physiological synthesis and proactive longevity modeling. The hardware introduction of the Apple Watch Series 12 and Apple Watch Ultra 4, coupled with the architectural overhaul of the Apple Health application under iOS 27, marks a significant convergence of high-frequency wearable photoplethysmography, on-device computer vision, g

For most of medical history, if you wanted to know what was happening inside a person's body, you had to break the skin. Blood is the gold standard for almost every biomarker clinicians care about, and getting at it means needles, vials, laboratories and waiting. Even the most celebrated success in wearable biosensing, the continuous glucose monitor, still relies on a filament pushed under the skin to sample interstitial fluid. Sweat has always been the obvious alternative. I

For most of the last three years, the story of metabolic health has been told as a pharmaceutical story. Semaglutide and tirzepatide rewrote the economics of obesity, turned Novo Nordisk and Eli Lilly into two of the most valuable companies in the world, and pulled a once-marginal clinical category into the centre of health policy. In the first nine months of 2025 alone, Lilly's Mounjaro and Zepbound generated $39.5 billion in revenue, overtaking Keytruda as the world's best-